Sun Pharma gains after USFDA nod for generic drug

Image
Capital Market
Last Updated : Oct 30 2017 | 12:01 AM IST

Sun Pharmaceutical Industries rose 1.94% to Rs 533.40 at 15:18 IST on BSE after the company said it received US drug regulator's approval for carvedilol phosphate extended release capsules.

The announcement was made during market hours today, 26 October 2017.

Meanwhile, the S&P BSE Sensex was up 10.72 points, or 0.03% to 33,053.22.

On the BSE, 2.84 lakh shares were traded in the counter so far, compared with average daily volumes of 4.95 lakh shares in the past one quarter. The stock had hit a high of Rs 538.75 and a low of Rs 519.50 so far during the day. The stock hit a 52-week high of Rs 753 on 28 October 2016. The stock hit a 52-week low of Rs 433.15 on 14 August 2017.

The stock had underperformed the market over the past one month till 25 October 2017, rising 3.11% compared with 4.57% rise in the Sensex. The scrip had also underperformed the market in past one quarter, falling 8.70% as against Sensex's 2.04% rise. The scrip had also underperformed the market in past one year, falling 29.25% as against Sensex's 18.70% rise.

The large-cap company has equity capital of Rs 239.93 crore. Face value per share is Re 1.

Sun Pharmaceutical Industries announced that one of its wholly-owned subsidiaries has received final approval from US Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for generic version of Coreg CR (carvedilol phosphate) extended release capsules, 10mg, 20mg, 40mg, 80 mg.

These generic carvedilol phosphate are therapeutic equivalents of GSK's Coreg CR extended release capsules. As per IMS, Coreg CR had annual sales of approximately $208 million in the US for the 12 months ended August 2017.

Sun Pharmaceutical Industries reported consolidated net loss of Rs 322.60 crore in Q1 June 2017 compared with net profit of Rs 2267.71 crore in Q1 June 2016. Net sales fell 23% to Rs 6166.66 crore in Q1 June 2017 over Q1 June 2016.

Sun Pharmaceutical Industries is a specialty generic pharmaceutical company and India's top pharmaceutical company.

Powered by Capital Market - Live News

Disclaimer: No Business Standard Journalist was involved in creation of this content

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Oct 26 2017 | 3:18 PM IST

Next Story